-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
47 410，8
8，
46，《8》，8。
，、，、410，8。，2，，。
，8——、、、、、、、，4+7。
As for the agreed procurement volume, Hubei Province stipulates that on the basis of the original procurement volume declared by various medical institutions in the pilot expansion, the procurement volume will be implemented in each medical insurance coordinating area and each medical institution.
The original selected (Hubei) varieties that are not selected in the bidding and meet the requirements of continuous online supply (not higher than the original selected price), the hospital purchases and uses within the remaining usage range, and the purchase amount is 20% of the agreed purchase amount calculation base, others The remaining consumption hospitals can purchase other non-selected varieties at reasonable prices.
Hubei’s notice clarified that on the one hand, the supply of non-selected varieties shall not be suspended across the board; on the other hand, all non-selected varieties shall be included in the monitoring and management, and the purchase amount shall not exceed the selected varieties.
It can be seen from Hubei’s documents that the original selected pharmaceutical companies in the 4+7 expansion will not be selected during the contract renewal stage of the centralized procurement, not only will the procurement volume be greatly reduced, but also will still face further price reduction requirements.
In general, in the renewal stage of centralized procurement, whether it is the original Chinese selected pharmaceutical company or the pharmaceutical company seeking market substitution, the pressure to reduce prices is not small.
In general, in the renewal stage of centralized procurement, whether it is the original Chinese selected pharmaceutical company or the pharmaceutical company seeking market substitution, the pressure to reduce prices is not small.
7 varieties, the selected pharmaceutical companies have changed
Judging from the supply catalog of the selected varieties, a total of 8 companies from the above 8 varieties were selected-the selected pharmaceutical companies are: Zhejiang Huahai Pharmaceutical, CSPC Ouyi Pharmaceutical, Sandoz (China) Pharmaceutical, Changzhou Pharmaceutical Factory, Jiangsu Wangao Pharmaceutical, Qilu Pharmaceutical (Hainan), Chongqing Shenghuaxi Pharmaceutical, Hunan Kelun Pharmaceutical.
According to Cybelan, the selected products of the above-mentioned selected pharmaceutical companies have passed the consistency evaluation after the first round of 4+7 centralized procurement and expansion.
It can be seen that as more pharmaceutical companies pass the consistency evaluation, some commonly used clinically The market competition for popular and large varieties is still fierce.
It can be seen that as more pharmaceutical companies pass the consistency evaluation, some commonly used clinically The market competition for popular and large varieties is still fierce.
Cyberlane inquired the list of selected drugs in the first round of 4+7 expansion alliance region (Hubei) and found that the selected pharmaceutical companies in Hubei for the above 8 types are: Zhejiang Huahai Pharmaceutical, Jiangsu Haosen Pharmaceutical, and Zhejiang Huahai Pharmaceuticals, Yangzijiang Pharmaceuticals, Hangzhou Merck Pharmaceuticals, Sichuan Huiyu Pharmaceuticals, Zhejiang Prokangyu Pharmaceuticals, Yangzijiang Pharmaceuticals.
From the above comparison, it can be seen that, except for paroxetine hydrochloride tablets (20mg*20 tablets), Huahai Pharmaceutical has maintained its qualification in Hubei at a 4+7 expanded selection price of 31.
18 yuan, and the other 7 varieties are selected.
Pharmaceutical companies have changed.
18 yuan, and the other 7 varieties are selected.
Pharmaceutical companies have changed.
In addition to paroxetine hydrochloride tablets (20mg*20 tablets), Huahai Pharmaceuticals also added a product specification in this collection in Hubei.
Paroxetine hydrochloride tablets (20mg*30 tablets), the price of which is 46.
08 yuan.
Paroxetine hydrochloride tablets (20mg*30 tablets), the price of which is 46.
08 yuan.
As for the latest selected pharmaceutical companies of the other 7 varieties, they finally won the qualification of the selection with a considerable price advantage-imatinib mesylate tablets (100mg*60 tablets), Sinopharm Ouyi Pharmaceutical's Zhongxuan website The price is 392 yuan, and the selected pharmaceutical company Jiangsu Hausen for the 4+7 expansion is 623 yuan, which is 231 yuan higher; compared with Yangzijiang Pharmaceutical, Kelun Pharmaceutical’s dexmedetomidine hydrochloride injection has dropped by as much as 93.
61%, the online price is 8.
5 yuan/piece; compared with the original winning bidders of Sichuan Huiyu Pharmaceutical and Yangzijiang Pharmaceutical, Qilu Pharmaceutical’s Pemetrexed Disodium for Injection, Changzhou Pharmaceutical Factory’s Enalapril maleate The sharp film also fell by more than 70%.
61%, the online price is 8.
5 yuan/piece; compared with the original winning bidders of Sichuan Huiyu Pharmaceutical and Yangzijiang Pharmaceutical, Qilu Pharmaceutical’s Pemetrexed Disodium for Injection, Changzhou Pharmaceutical Factory’s Enalapril maleate The sharp film also fell by more than 70%.
It is worth noting that among the 8 newly selected pharmaceutical companies, one is a multinational pharmaceutical company Sandoz, which selected Losartan Potassium Tablets (50mg*30) at a price of 29.
1 yuan, which is comparable to the original selected pharmaceutical company Zhejiang Huahai Compared with the selection of the pharmaceutical industry at a price of 14.
7 yuan (50mg*14), it won with a slight price advantage.
1 yuan, which is comparable to the original selected pharmaceutical company Zhejiang Huahai Compared with the selection of the pharmaceutical industry at a price of 14.
7 yuan (50mg*14), it won with a slight price advantage.
From the stage of centralized drug procurement organized by the state, domestic generic drug companies have realized multi-variety selection based on price advantages and began to replace original research drugs.
To the stage of centralized procurement renewal, multinational pharmaceutical companies have begun to seek to divide some varieties of drugs.
The purchase amount within the policy can give a glimpse of the national organization of drugs.
The price reduction and subsequent effects of the centralized procurement policy.
To the stage of centralized procurement renewal, multinational pharmaceutical companies have begun to seek to divide some varieties of drugs.
The purchase amount within the policy can give a glimpse of the national organization of drugs.
The price reduction and subsequent effects of the centralized procurement policy.
Centralized procurement expansion and contract renewal, competition between pharmaceutical companies continues
The first round of 4+7 centralized procurement: 11 pilot cities, 25 varieties, a 12-month procurement cycle, the centralized procurement document was released on November 15, 2018, and the official results were released on December 7, 2018, and 2-3 in 2019 It will land in the next month, that is to say, by February-February 2020, the results of the first round of centralized procurement will be basically implemented.
Among the 11 pilot cities, Beijing, Tianjin, Shanghai, and Chongqing are also expected to need to renew their contracts independently because they are not part of the 25 alliance regions.
As for the seven cities of Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi'an, they may be merged into the corresponding provinces to carry out contract renewal.
As for the seven cities of Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi'an, they may be merged into the corresponding provinces to carry out contract renewal.
4+7 expansion: Covering 25 alliance regions.
According to the regulations of the alliance region's centralized procurement documents, the selected company does not exceed 2 (including) varieties, and the procurement cycle is in principle 1 year; the selected company is the product of 3 varieties.
In principle, the cycle is 2 years.
The procurement cycle can be extended by one year depending on the actual situation, that is, up to 3 years.
According to the regulations of the alliance region's centralized procurement documents, the selected company does not exceed 2 (including) varieties, and the procurement cycle is in principle 1 year; the selected company is the product of 3 varieties.
In principle, the cycle is 2 years.
The procurement cycle can be extended by one year depending on the actual situation, that is, up to 3 years.
On September 1, 2019, the 4+7 centralized procurement expansion released the centralized procurement documents, and the results of the centralized procurement were announced on September 25, 2019.
The first round of centralized procurement was expanded to the whole country.
According to calculations based on the time it took for the centralized procurement to land, the procurement cycle for varieties with a one-year procurement cycle has basically ended and the centralized procurement renewal phase has also entered.
The first round of centralized procurement was expanded to the whole country.
According to calculations based on the time it took for the centralized procurement to land, the procurement cycle for varieties with a one-year procurement cycle has basically ended and the centralized procurement renewal phase has also entered.
Take Hubei as an example-on December 7, 2020, Hubei Province issued a relevant notice clarifying that it will renew 11 types of products with no more than 2 selected companies (inclusive) and a procurement cycle of 1 year in principle.
Encourage qualified original research drug companies and pilot expansion procurement cycles to actively participate in generic drug companies through the consistency evaluation of the same product regulations in the procurement cycle.
What Hubei has adopted is to carry out contract renewal and bidding work by adopting the method of "inquiry before bidding" on the basis of ensuring that enterprises, market expectations and price levels are relatively stable.
There are 1 or 2 companies that were originally selected, and there are no new drugs that have been reviewed .
Inquire whether the originally selected company agrees to renew the contract at the original selected price of the pilot expansion (Hubei).
Inquire whether the originally selected company agrees to renew the contract at the original selected price of the pilot expansion (Hubei).
The original selected company is 1 or 2, and there are new drugs that have been reviewed.
Inquire whether the newly-reviewed drug companies and the unselected original research drug companies in the alliance area are interested in supplying Hubei and participating in the bidding.
Inquire whether the newly-reviewed drug companies and the unselected original research drug companies in the alliance area are interested in supplying Hubei and participating in the bidding.
The bidding will be carried out on the basis of the completion of the consultation of relevant enterprises' opinions.
The lowest price of the original selected price is the highest effective quotation, and the lowest price after the bidding is the newly selected company-that is to say, if you want to successfully win the market share of the collectively sourced varieties during the renewal phase, you need to be more than the original selected price Lower.
The lowest price of the original selected price is the highest effective quotation, and the lowest price after the bidding is the newly selected company-that is to say, if you want to successfully win the market share of the collectively sourced varieties during the renewal phase, you need to be more than the original selected price Lower.
According to the regulations of Hubei Province, before the implementation of the new procurement cycle, the bidding products will be supplied by the original selected company at the original selected price.
However, starting from April 10, the original market share of the selected pharmaceutical companies will be sold to the newly selected pharmaceutical companies.
With the official implementation of the new online prices, the low prices of related centralized procurement products have been further refreshed.
However, starting from April 10, the original market share of the selected pharmaceutical companies will be sold to the newly selected pharmaceutical companies.
With the official implementation of the new online prices, the low prices of related centralized procurement products have been further refreshed.
And it must be noted that, in addition to Hubei Province, Heilongjiang, Shanxi, Xinjiang, Liaoning, Guizhou and other regions are also renewing the procurement of expired varieties of centralized procurement, in addition to the first procurement cycle of the national organization of centralized drug procurement.
In addition to contention, price wars among relevant pharmaceutical companies are still continuing during the contract renewal phase.
In addition to contention, price wars among relevant pharmaceutical companies are still continuing during the contract renewal phase.
Medical News, April 7th, from April 10th, the results of the collection of 8 major varieties will be officially implemented
8 major varieties, the results of centralized procurement will be implemented
On April 6, the Hubei Province Pharmaceutical Price and Bidding Procurement Management Service Network issued the "Notice on the Implementation of the Results of the Centralized Procurement of 8 Varieties of Paroxetine Oral Constant Release Formulations", expanding the Hubei Province implementation of the nationally organized drug centralized procurement pilot to paroxetine The results of the centralized procurement of 8 varieties of oral regular-release dosage forms were notified.
According to the notice, public medical institutions at all levels and various types of medical institutions in Hubei Province, as well as medical insurance designated social medical institutions and medical insurance designated retail pharmacies that voluntarily participate in Hubei Province will implement centralized procurement of 8 varieties from April 10th.
result.
Starting from the date of implementation, the current round of procurement cycle is in principle 2 years, during the procurement cycle, the procurement agreement is signed every year.
result.
Starting from the date of implementation, the current round of procurement cycle is in principle 2 years, during the procurement cycle, the procurement agreement is signed every year.
According to Cyberlan, the 8 varieties collected in this round in Hubei are: Paroxetine Hydrochloride Tablets, Imatinib Mesylate Tablets, Losartan Potassium Tablets, Enalapril Maleate Tablets, Montelux Special sodium tablets, pemetrexed disodium for injection, levetiracetam tablets, and dexmedetomidine hydrochloride injection are all 4+7 varieties in the first round.
As for the agreed procurement volume, Hubei Province stipulates that on the basis of the original procurement volume declared by various medical institutions in the pilot expansion, the procurement volume will be implemented in each medical insurance coordinating area and each medical institution.
The original selected (Hubei) varieties that are not selected in the bidding and meet the requirements of continuous online supply (not higher than the original selected price), the hospital purchases and uses within the remaining usage range, and the purchase amount is 20% of the agreed purchase amount calculation base, others The remaining consumption hospitals can purchase other non-selected varieties at reasonable prices.
Hubei’s notice clarified that on the one hand, the supply of non-selected varieties shall not be suspended across the board; on the other hand, all non-selected varieties shall be included in the monitoring and management, and the purchase amount shall not exceed the selected varieties.
It can be seen from Hubei’s documents that the original selected pharmaceutical companies in the 4+7 expansion will not be selected during the contract renewal stage of the centralized procurement, not only will the procurement volume be greatly reduced, but also will still face further price reduction requirements.
In general, in the renewal stage of centralized procurement, whether it is the original Chinese selected pharmaceutical company or the pharmaceutical company seeking market substitution, the pressure to reduce prices is not small.
In general, in the renewal stage of centralized procurement, whether it is the original Chinese selected pharmaceutical company or the pharmaceutical company seeking market substitution, the pressure to reduce prices is not small.
7 varieties, the selected pharmaceutical companies have changed
Judging from the supply catalog of the selected varieties, a total of 8 companies from the above 8 varieties were selected-the selected pharmaceutical companies are: Zhejiang Huahai Pharmaceutical, CSPC Ouyi Pharmaceutical, Sandoz (China) Pharmaceutical, Changzhou Pharmaceutical Factory, Jiangsu Wangao Pharmaceutical, Qilu Pharmaceutical (Hainan), Chongqing Shenghuaxi Pharmaceutical, Hunan Kelun Pharmaceutical.
According to Cybelan, the selected products of the above-mentioned selected pharmaceutical companies have passed the consistency evaluation after the first round of 4+7 centralized procurement and expansion.
It can be seen that as more pharmaceutical companies pass the consistency evaluation, some commonly used clinically The market competition for popular and large varieties is still fierce.
It can be seen that as more pharmaceutical companies pass the consistency evaluation, some commonly used clinically The market competition for popular and large varieties is still fierce.
Cyberlane inquired the list of selected drugs in the first round of 4+7 expansion alliance region (Hubei) and found that the selected pharmaceutical companies in Hubei for the above 8 types are: Zhejiang Huahai Pharmaceutical, Jiangsu Haosen Pharmaceutical, and Zhejiang Huahai Pharmaceuticals, Yangzijiang Pharmaceuticals, Hangzhou Merck Pharmaceuticals, Sichuan Huiyu Pharmaceuticals, Zhejiang Prokangyu Pharmaceuticals, Yangzijiang Pharmaceuticals.
From the above comparison, it can be seen that, except for paroxetine hydrochloride tablets (20mg*20 tablets), Huahai Pharmaceutical has maintained its qualification in Hubei at a 4+7 expanded selection price of 31.
18 yuan, and the other 7 varieties are selected.
Pharmaceutical companies have changed.
18 yuan, and the other 7 varieties are selected.
Pharmaceutical companies have changed.
In addition to paroxetine hydrochloride tablets (20mg*20 tablets), Huahai Pharmaceuticals also added a product specification in this collection in Hubei.
Paroxetine hydrochloride tablets (20mg*30 tablets), the price of which is 46.
08 yuan.
Paroxetine hydrochloride tablets (20mg*30 tablets), the price of which is 46.
08 yuan.
As for the latest selected pharmaceutical companies of the other 7 varieties, they finally won the qualification of the selection with a considerable price advantage-imatinib mesylate tablets (100mg*60 tablets), Sinopharm Ouyi Pharmaceutical's Zhongxuan website The price is 392 yuan, and the selected pharmaceutical company Jiangsu Hausen for the 4+7 expansion is 623 yuan, which is 231 yuan higher; compared with Yangzijiang Pharmaceutical, Kelun Pharmaceutical’s dexmedetomidine hydrochloride injection has dropped by as much as 93.
61%, the online price is 8.
5 yuan/piece; compared with the original winning bidders of Sichuan Huiyu Pharmaceutical and Yangzijiang Pharmaceutical, Qilu Pharmaceutical’s Pemetrexed Disodium for Injection, Changzhou Pharmaceutical Factory’s Enalapril maleate The sharp film also fell by more than 70%.
61%, the online price is 8.
5 yuan/piece; compared with the original winning bidders of Sichuan Huiyu Pharmaceutical and Yangzijiang Pharmaceutical, Qilu Pharmaceutical’s Pemetrexed Disodium for Injection, Changzhou Pharmaceutical Factory’s Enalapril maleate The sharp film also fell by more than 70%.
It is worth noting that among the 8 newly selected pharmaceutical companies, one is a multinational pharmaceutical company Sandoz, which selected Losartan Potassium Tablets (50mg*30) at a price of 29.
1 yuan, which is comparable to the original selected pharmaceutical company Zhejiang Huahai Compared with the selection of the pharmaceutical industry at a price of 14.
7 yuan (50mg*14), it won with a slight price advantage.
1 yuan, which is comparable to the original selected pharmaceutical company Zhejiang Huahai Compared with the selection of the pharmaceutical industry at a price of 14.
7 yuan (50mg*14), it won with a slight price advantage.
From the stage of centralized drug procurement organized by the state, domestic generic drug companies have realized multi-variety selection based on price advantages and began to replace original research drugs.
To the stage of centralized procurement renewal, multinational pharmaceutical companies have begun to seek to divide some varieties of drugs.
The purchase amount within the policy can give a glimpse of the national organization of drugs.
The price reduction and subsequent effects of the centralized procurement policy.
To the stage of centralized procurement renewal, multinational pharmaceutical companies have begun to seek to divide some varieties of drugs.
The purchase amount within the policy can give a glimpse of the national organization of drugs.
The price reduction and subsequent effects of the centralized procurement policy.
Centralized procurement expansion and contract renewal, competition between pharmaceutical companies continues
The first round of 4+7 centralized procurement: 11 pilot cities, 25 varieties, a 12-month procurement cycle, the centralized procurement document was released on November 15, 2018, and the official results were released on December 7, 2018, and 2-3 in 2019 It will land in the next month, that is to say, by February-February 2020, the results of the first round of centralized procurement will be basically implemented.
Among the 11 pilot cities, Beijing, Tianjin, Shanghai, and Chongqing are also expected to need to renew their contracts independently because they are not part of the 25 alliance regions.
As for the seven cities of Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi'an, they may be merged into the corresponding provinces to carry out contract renewal.
As for the seven cities of Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi'an, they may be merged into the corresponding provinces to carry out contract renewal.
4+7 expansion: Covering 25 alliance regions.
According to the regulations of the alliance region's centralized procurement documents, the selected company does not exceed 2 (including) varieties, and the procurement cycle is in principle 1 year; the selected company is the product of 3 varieties.
In principle, the cycle is 2 years.
The procurement cycle can be extended by one year depending on the actual situation, that is, up to 3 years.
According to the regulations of the alliance region's centralized procurement documents, the selected company does not exceed 2 (including) varieties, and the procurement cycle is in principle 1 year; the selected company is the product of 3 varieties.
In principle, the cycle is 2 years.
The procurement cycle can be extended by one year depending on the actual situation, that is, up to 3 years.
On September 1, 2019, the 4+7 centralized procurement expansion released the centralized procurement documents, and the results of the centralized procurement were announced on September 25, 2019.
The first round of centralized procurement was expanded to the whole country.
According to calculations based on the time it took for the centralized procurement to land, the procurement cycle for varieties with a one-year procurement cycle has basically ended and the centralized procurement renewal phase has also entered.
The first round of centralized procurement was expanded to the whole country.
According to calculations based on the time it took for the centralized procurement to land, the procurement cycle for varieties with a one-year procurement cycle has basically ended and the centralized procurement renewal phase has also entered.
Take Hubei as an example-on December 7, 2020, Hubei Province issued a relevant notice clarifying that it will renew 11 types of products with no more than 2 selected companies (inclusive) and a procurement cycle of 1 year in principle.
Encourage qualified original research drug companies and pilot expansion procurement cycles to actively participate in generic drug companies through the consistency evaluation of the same product regulations in the procurement cycle.
What Hubei has adopted is to carry out contract renewal and bidding work by adopting the method of "inquiry before bidding" on the basis of ensuring that enterprises, market expectations and price levels are relatively stable.
There are 1 or 2 companies that were originally selected, and there are no new drugs that have been reviewed .
Inquire whether the originally selected company agrees to renew the contract at the original selected price of the pilot expansion (Hubei).
Inquire whether the originally selected company agrees to renew the contract at the original selected price of the pilot expansion (Hubei).
The original selected company is 1 or 2, and there are new drugs that have been reviewed.
Inquire whether the newly-reviewed drug companies and the unselected original research drug companies in the alliance area are interested in supplying Hubei and participating in the bidding.
Inquire whether the newly-reviewed drug companies and the unselected original research drug companies in the alliance area are interested in supplying Hubei and participating in the bidding.
The bidding will be carried out on the basis of the completion of the consultation of relevant enterprises' opinions.
The lowest price of the original selected price is the highest effective quotation, and the lowest price after the bidding is the newly selected company-that is to say, if you want to successfully win the market share of the collectively sourced varieties during the renewal phase, you need to be more than the original selected price Lower.
The lowest price of the original selected price is the highest effective quotation, and the lowest price after the bidding is the newly selected company-that is to say, if you want to successfully win the market share of the collectively sourced varieties during the renewal phase, you need to be more than the original selected price Lower.
According to the regulations of Hubei Province, before the implementation of the new procurement cycle, the bidding products will be supplied by the original selected company at the original selected price.
However, starting from April 10, the original market share of the selected pharmaceutical companies will be sold to the newly selected pharmaceutical companies.
With the official implementation of the new online prices, the low prices of related centralized procurement products have been further refreshed.
However, starting from April 10, the original market share of the selected pharmaceutical companies will be sold to the newly selected pharmaceutical companies.
With the official implementation of the new online prices, the low prices of related centralized procurement products have been further refreshed.
And it must be noted that, in addition to Hubei Province, Heilongjiang, Shanxi, Xinjiang, Liaoning, Guizhou and other regions are also renewing the procurement of expired varieties of centralized procurement, in addition to the first procurement cycle of the national organization of centralized drug procurement.
In addition to contention, price wars among relevant pharmaceutical companies are still continuing during the contract renewal phase.
In addition to contention, price wars among relevant pharmaceutical companies are still continuing during the contract renewal phase.
Medical News, April 7th, from April 10th, the results of the collection of 8 major varieties will be officially implemented
8 major varieties, the results of centralized procurement will be implemented
8 major varieties, the results of centralized procurement will be implemented On April 6, the Hubei Province Pharmaceutical Price and Bidding Procurement Management Service Network issued the "Notice on the Implementation of the Results of the Centralized Procurement of 8 Varieties of Paroxetine Oral Constant Release Formulations", expanding the Hubei Province implementation of the nationally organized drug centralized procurement pilot to paroxetine The results of the centralized procurement of 8 varieties of oral regular-release dosage forms were notified.
Medicine Medicine Medicine According to the notice, public medical institutions at all levels and various types of medical institutions in Hubei Province, as well as medical insurance designated social medical institutions and medical insurance designated retail pharmacies that voluntarily participate in Hubei Province will implement centralized procurement of 8 varieties from April 10th.
result.
Starting from the date of implementation, the current round of procurement cycle is in principle 2 years, during the procurement cycle, the procurement agreement is signed every year.
Pharmacy pharmacy pharmacyresult.
Starting from the date of implementation, the current round of procurement cycle is in principle 2 years, during the procurement cycle, the procurement agreement is signed every year.
According to Cyberlan, the 8 varieties collected in this round in Hubei are: Paroxetine Hydrochloride Tablets, Imatinib Mesylate Tablets, Losartan Potassium Tablets, Enalapril Maleate Tablets, Montelux Special sodium tablets, pemetrexed disodium for injection, levetiracetam tablets, and dexmedetomidine hydrochloride injection are all 4+7 varieties in the first round.
As for the agreed procurement volume, Hubei Province stipulates that on the basis of the original procurement volume declared by various medical institutions in the pilot expansion, the procurement volume will be implemented in each medical insurance coordinating area and each medical institution.
The original selected (Hubei) varieties that are not selected in the bidding and meet the requirements of continuous online supply (not higher than the original selected price), the hospital purchases and uses within the remaining usage range, and the purchase amount is 20% of the agreed purchase amount calculation base, others The remaining consumption hospitals can purchase other non-selected varieties at reasonable prices.
Hospital hospital hospital Hubei’s notice clarified that on the one hand, the supply of non-selected varieties shall not be suspended across the board; on the other hand, all non-selected varieties shall be included in the monitoring and management, and the purchase amount shall not exceed the selected varieties.
It can be seen from Hubei’s documents that the original selected pharmaceutical companies in the 4+7 expansion will not be selected during the contract renewal stage of the centralized procurement, not only will the procurement volume be greatly reduced, but also will still face further price reduction requirements.
In general, in the renewal stage of centralized procurement, whether it is the original Chinese selected pharmaceutical company or the pharmaceutical company seeking market substitution, the pressure to reduce prices is not small.
In general, in the renewal stage of centralized procurement, whether it is the original Chinese selected pharmaceutical company or the pharmaceutical company seeking market substitution, the pressure to reduce prices is not small.
7 varieties, the selected pharmaceutical companies have changed
7 varieties, the selected pharmaceutical companies have changed Judging from the supply catalog of the selected varieties, a total of 8 companies from the above 8 varieties were selected-the selected pharmaceutical companies are: Zhejiang Huahai Pharmaceutical, CSPC Ouyi Pharmaceutical, Sandoz (China) Pharmaceutical, Changzhou Pharmaceutical Factory, Jiangsu Wangao Pharmaceutical, Qilu Pharmaceutical (Hainan), Chongqing Shenghuaxi Pharmaceutical, Hunan Kelun Pharmaceutical.
Enterprise business enterprise According to Cybelan, the selected products of the above-mentioned selected pharmaceutical companies have passed the consistency evaluation after the first round of 4+7 centralized procurement and expansion.
It can be seen that as more pharmaceutical companies pass the consistency evaluation, some commonly used clinically The market competition for popular and large varieties is still fierce.
It can be seen that as more pharmaceutical companies pass the consistency evaluation, some commonly used clinically The market competition for popular and large varieties is still fierce.
Cyberlane inquired the list of selected drugs in the first round of 4+7 expansion alliance region (Hubei) and found that the selected pharmaceutical companies in Hubei for the above 8 types are: Zhejiang Huahai Pharmaceutical, Jiangsu Haosen Pharmaceutical, and Zhejiang Huahai Pharmaceuticals, Yangzijiang Pharmaceuticals, Hangzhou Merck Pharmaceuticals, Sichuan Huiyu Pharmaceuticals, Zhejiang Prokangyu Pharmaceuticals, Yangzijiang Pharmaceuticals.
From the above comparison, it can be seen that, except for paroxetine hydrochloride tablets (20mg*20 tablets), Huahai Pharmaceutical has maintained its qualification in Hubei at a 4+7 expanded selection price of 31.
18 yuan, and the other 7 varieties are selected.
Pharmaceutical companies have changed.
18 yuan, and the other 7 varieties are selected.
Pharmaceutical companies have changed.
In addition to paroxetine hydrochloride tablets (20mg*20 tablets), Huahai Pharmaceuticals also added a product specification in this collection in Hubei.
Paroxetine hydrochloride tablets (20mg*30 tablets), the price of which is 46.
08 yuan.
Paroxetine hydrochloride tablets (20mg*30 tablets), the price of which is 46.
08 yuan.
As for the latest selected pharmaceutical companies of the other 7 varieties, they finally won the qualification of the selection with a considerable price advantage-imatinib mesylate tablets (100mg*60 tablets), Sinopharm Ouyi Pharmaceutical's Zhongxuan website The price is 392 yuan, and the selected pharmaceutical company Jiangsu Hausen for the 4+7 expansion is 623 yuan, which is 231 yuan higher; compared with Yangzijiang Pharmaceutical, Kelun Pharmaceutical’s dexmedetomidine hydrochloride injection has dropped by as much as 93.
61%, the online price is 8.
5 yuan/piece; compared with the original winning bidders of Sichuan Huiyu Pharmaceutical and Yangzijiang Pharmaceutical, Qilu Pharmaceutical’s Pemetrexed Disodium for Injection, Changzhou Pharmaceutical Factory’s Enalapril maleate The sharp film also fell by more than 70%.
61%, the online price is 8.
5 yuan/piece; compared with the original winning bidders of Sichuan Huiyu Pharmaceutical and Yangzijiang Pharmaceutical, Qilu Pharmaceutical’s Pemetrexed Disodium for Injection, Changzhou Pharmaceutical Factory’s Enalapril maleate The sharp film also fell by more than 70%.
It is worth noting that among the 8 newly selected pharmaceutical companies, one is a multinational pharmaceutical company Sandoz, which selected Losartan Potassium Tablets (50mg*30) at a price of 29.
1 yuan, which is comparable to the original selected pharmaceutical company Zhejiang Huahai Compared with the selection of the pharmaceutical industry at a price of 14.
7 yuan (50mg*14), it won with a slight price advantage.
1 yuan, which is comparable to the original selected pharmaceutical company Zhejiang Huahai Compared with the selection of the pharmaceutical industry at a price of 14.
7 yuan (50mg*14), it won with a slight price advantage.
From the stage of centralized drug procurement organized by the state, domestic generic drug companies have realized multi-variety selection based on price advantages and began to replace original research drugs.
To the stage of centralized procurement renewal, multinational pharmaceutical companies have begun to seek to divide some varieties of drugs.
The purchase amount within the policy can give a glimpse of the national organization of drugs.
The price reduction and subsequent effects of the centralized procurement policy.
To the stage of centralized procurement renewal, multinational pharmaceutical companies have begun to seek to divide some varieties of drugs.
The purchase amount within the policy can give a glimpse of the national organization of drugs.
The price reduction and subsequent effects of the centralized procurement policy.
Centralized procurement expansion and contract renewal, competition between pharmaceutical companies continues
Centralized procurement expansion and contract renewal, competition between pharmaceutical companies continues The first round of 4+7 centralized procurement: 11 pilot cities, 25 varieties, a 12-month procurement cycle, the centralized procurement document was released on November 15, 2018, and the official results were released on December 7, 2018, and 2-3 in 2019 It will land in the next month, that is to say, by February-February 2020, the results of the first round of centralized procurement will be basically implemented.
Among the 11 pilot cities, Beijing, Tianjin, Shanghai, and Chongqing are also expected to need to renew their contracts independently because they are not part of the 25 alliance regions.
As for the seven cities of Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi'an, they may be merged into the corresponding provinces to carry out contract renewal.
As for the seven cities of Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi'an, they may be merged into the corresponding provinces to carry out contract renewal.
4+7 expansion: Covering 25 alliance regions.
According to the regulations of the alliance region's centralized procurement documents, the selected company does not exceed 2 (including) varieties, and the procurement cycle is in principle 1 year; the selected company is the product of 3 varieties.
In principle, the cycle is 2 years.
The procurement cycle can be extended by one year depending on the actual situation, that is, up to 3 years.
According to the regulations of the alliance region's centralized procurement documents, the selected company does not exceed 2 (including) varieties, and the procurement cycle is in principle 1 year; the selected company is the product of 3 varieties.
In principle, the cycle is 2 years.
The procurement cycle can be extended by one year depending on the actual situation, that is, up to 3 years.
On September 1, 2019, the 4+7 centralized procurement expansion released the centralized procurement documents, and the results of the centralized procurement were announced on September 25, 2019.
The first round of centralized procurement was expanded to the whole country.
According to calculations based on the time it took for the centralized procurement to land, the procurement cycle for varieties with a one-year procurement cycle has basically ended and the centralized procurement renewal phase has also entered.
The first round of centralized procurement was expanded to the whole country.
According to calculations based on the time it took for the centralized procurement to land, the procurement cycle for varieties with a one-year procurement cycle has basically ended and the centralized procurement renewal phase has also entered.
Take Hubei as an example-on December 7, 2020, Hubei Province issued a relevant notice clarifying that it will renew 11 types of products with no more than 2 selected companies (inclusive) and a procurement cycle of 1 year in principle.
Encourage qualified original research drug companies and pilot expansion procurement cycles to actively participate in generic drug companies through the consistency evaluation of the same product regulations in the procurement cycle.
What Hubei has adopted is to carry out contract renewal and bidding work by adopting the method of "inquiry before bidding" on the basis of ensuring that enterprises, market expectations and price levels are relatively stable.
There are 1 or 2 companies that were originally selected, and there are no new drugs that have been reviewed .
Inquire whether the originally selected company agrees to renew the contract at the original selected price of the pilot expansion (Hubei).
Medicine, medicine, medicineInquire whether the originally selected company agrees to renew the contract at the original selected price of the pilot expansion (Hubei).
The original selected company is 1 or 2, and there are new drugs that have been reviewed.
Inquire whether the newly-reviewed drug companies and the unselected original research drug companies in the alliance area are interested in supplying Hubei and participating in the bidding.
Inquire whether the newly-reviewed drug companies and the unselected original research drug companies in the alliance area are interested in supplying Hubei and participating in the bidding.
The bidding will be carried out on the basis of the completion of the consultation of relevant enterprises' opinions.
The lowest price of the original selected price is the highest effective quotation, and the lowest price after the bidding is the newly selected company-that is to say, if you want to successfully win the market share of the collectively sourced varieties during the renewal phase, you need to be more than the original selected price Lower.
The lowest price of the original selected price is the highest effective quotation, and the lowest price after the bidding is the newly selected company-that is to say, if you want to successfully win the market share of the collectively sourced varieties during the renewal phase, you need to be more than the original selected price Lower.
According to the regulations of Hubei Province, before the implementation of the new procurement cycle, the bidding products will be supplied by the original selected company at the original selected price.
However, starting from April 10, the original market share of the selected pharmaceutical companies will be sold to the newly selected pharmaceutical companies.
With the official implementation of the new online prices, the low prices of related centralized procurement products have been further refreshed.
However, starting from April 10, the original market share of the selected pharmaceutical companies will be sold to the newly selected pharmaceutical companies.
With the official implementation of the new online prices, the low prices of related centralized procurement products have been further refreshed.
And it must be noted that, in addition to Hubei Province, Heilongjiang, Shanxi, Xinjiang, Liaoning, Guizhou and other regions are also renewing the procurement of expired varieties of centralized procurement, in addition to the first procurement cycle of the national organization of centralized drug procurement.
In addition to contention, price wars among relevant pharmaceutical companies are still continuing during the contract renewal phase.
In addition to contention, price wars among relevant pharmaceutical companies are still continuing during the contract renewal phase.
